Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease

Journal of Clinical Pharmacology

Volumn 41, Issue 10, 2001, Pages 1082-1090

  Gobburu, J V S ^a   Tammara, V ^a   Lesko, L ^a   Jhee, S S ^a   Sramek, J J ^a   Cutler, N R ^a   Yuan, R ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DRUG METABOLITE; NAP 226 90; RIVASTIGMINE; UNCLASSIFIED DRUG; ZNS 114 666;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; PHARMACODYNAMICS;

ACETYLCHOLINESTERASE; AGED; ALZHEIMER DISEASE; CARBAMATES; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEUROPSYCHOLOGICAL TESTS; PATIENTS; PHENYLCARBAMATES;

EID: 0034836278     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122012689     Document Type: Article

References (17)

1. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease
2. A new and rapid colorimetric determination of acetylcholinesterase activity
3. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine
4. Paracetamol plasma and cembrospinal fluid pharmacokinetics in children
5. Conceptualization of drug distribution to a hypothetical pharmacodynamic effect compartment
6. Results and validation of a population pharmacodynamic model for cognitive effect in Alzheimer patients treated with tacrine
7. The efficacy of xanomeline in Alzheimer disease: Cognitive improvement measured using the computerized neuropsychological test battery (CNTB)
8. Disposition of SDZ ENA 713, an acetylcholinesterase inhibitor, in the rabbit
9. 14C]SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration
10. Pharmacokinetics of rivastigmine and its metabolite following a single oral 6 mg dose versus a single 2 mg iv dose in patients with Alzheimer's disease
11. Absolute bioavailability of rivastigmine using Michaelis-Menten kinetics
12. Distributed model for drug delivery to CSF and brain tissue
13. Clinical development of Exelon (ENA 713): The ADENA programme
14. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans
15. Prevalence of clinically diagnosed Alzheimer's disease and other dementing disorders: A door-to-door survey in Appignano, Macerata Province, Italy
16. A new assessment tool for neuropsychopharmacologic research: The computerized neuropsychological test battery